COVID‐19 pandemic and allergen immunotherapy—an EAACI survey
Background As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different coun...
Gespeichert in:
| Veröffentlicht in: | Allergy (Copenhagen) 2021-11, Vol.76 (11), p.3504-3516 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3516 |
|---|---|
| container_issue | 11 |
| container_start_page | 3504 |
| container_title | Allergy (Copenhagen) |
| container_volume | 76 |
| creator | Pfaar, Oliver Agache, Ioana Bonini, Matteo Brough, Helen Annaruth Chivato, Tomás Del Giacco, Stefano R. Gawlik, Radoslaw Gelincik, Aslı Hoffmann‐Sommergruber, Karin Jutel, Marek Klimek, Ludger Knol, Edward F. Lauerma, Antti Ollert, Markus O’Mahony, Liam Mortz, Charlotte G. Palomares, Oscar Riggioni, Carmen Schwarze, Jürgen Skypala, Isabel Torres, María José Untersmayr, Eva Walusiak‐Skorupa, Jolanta Chaker, Adam Giovannini, Mattia Heffler, Enrico Jensen‐Jarolim, Erika Quecchia, Cristina Sandoval‐Ruballos, Mónica Sahiner, Umit Tomić Spirić, Vesna Alvaro‐Lozano, Montserrat |
| description | Background
As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.
Methods
Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set‐up a web‐based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine.
Results
417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID‐19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2).
Conclusions
This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID‐19 pandemic and gave no concerns regarding reduced tolerability under real‐life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long‐lasting negative impact on the clinical care of allergic patients.
This is the first report of an international retrospective survey in atopic diseases investigating practical aspects and tolerability of AIT during the COVID‐19 pandemic. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT, 35% SLIT, and 40% venom AIT in the induction phase of AIT though planned. For the maintenance phase of AIT, SCIT was performed by 75%, SLIT by 89%, and venom AIT by 74% of the respondents as regularly planned. Data indicate a (temporary) undertreatment of AIT, but gave no concerns regarding reduced tolerability under real‐life circumstances. Abbreviations: AIT, allergen immunotherapy |
| doi_str_mv | 10.1111/all.14793 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8013670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586808866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4713-83b28a51e46158c11ed102afe8b0bee448d40549952606ecbe93cacefb496c163</originalsourceid><addsrcrecordid>eNp1kMtOAjEUhhujEUQXvoCZxJWLgXZ6od0YCaKSkLBRt02nHGDIXLDDYNjxCC58Qp7EIkh04dmcxfnynT8_QpcEN4mflknTJmFtRY9QnVAlQ6UUP0Z1TDAPGaeyhs7KcoYxbkcKn6IapYJzTlQd3XWHr_37zfqDqGBu8hFkiQ38DrwT3ATyIMmyKi8WU3BmvtqsP00e9Dqdbj8oK7eE1Tk6GZu0hIv9bqCXh95z9ykcDB_73c4gtKxNaChpHEnDCTBBuLSEwIjgyIxBxjgGYEyOGObM544EFmBjUNQaC-OYKWGJoA10u_POqziDkYV84Uyq5y7JjFvpwiT67yVPpnpSLLXEhIo29oLrvcAVbxWUCz0rKpf7zDriUkgspdi-udlR1hVl6WB8-ECw3patfTH6u2zPXv2OdCB_2vVAawe8Jyms_jfpzmCwU34BOkCKBA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586808866</pqid></control><display><type>article</type><title>COVID‐19 pandemic and allergen immunotherapy—an EAACI survey</title><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pfaar, Oliver ; Agache, Ioana ; Bonini, Matteo ; Brough, Helen Annaruth ; Chivato, Tomás ; Del Giacco, Stefano R. ; Gawlik, Radoslaw ; Gelincik, Aslı ; Hoffmann‐Sommergruber, Karin ; Jutel, Marek ; Klimek, Ludger ; Knol, Edward F. ; Lauerma, Antti ; Ollert, Markus ; O’Mahony, Liam ; Mortz, Charlotte G. ; Palomares, Oscar ; Riggioni, Carmen ; Schwarze, Jürgen ; Skypala, Isabel ; Torres, María José ; Untersmayr, Eva ; Walusiak‐Skorupa, Jolanta ; Chaker, Adam ; Giovannini, Mattia ; Heffler, Enrico ; Jensen‐Jarolim, Erika ; Quecchia, Cristina ; Sandoval‐Ruballos, Mónica ; Sahiner, Umit ; Tomić Spirić, Vesna ; Alvaro‐Lozano, Montserrat</creator><creatorcontrib>Pfaar, Oliver ; Agache, Ioana ; Bonini, Matteo ; Brough, Helen Annaruth ; Chivato, Tomás ; Del Giacco, Stefano R. ; Gawlik, Radoslaw ; Gelincik, Aslı ; Hoffmann‐Sommergruber, Karin ; Jutel, Marek ; Klimek, Ludger ; Knol, Edward F. ; Lauerma, Antti ; Ollert, Markus ; O’Mahony, Liam ; Mortz, Charlotte G. ; Palomares, Oscar ; Riggioni, Carmen ; Schwarze, Jürgen ; Skypala, Isabel ; Torres, María José ; Untersmayr, Eva ; Walusiak‐Skorupa, Jolanta ; Chaker, Adam ; Giovannini, Mattia ; Heffler, Enrico ; Jensen‐Jarolim, Erika ; Quecchia, Cristina ; Sandoval‐Ruballos, Mónica ; Sahiner, Umit ; Tomić Spirić, Vesna ; Alvaro‐Lozano, Montserrat</creatorcontrib><description>Background
As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.
Methods
Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set‐up a web‐based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine.
Results
417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID‐19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2).
Conclusions
This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID‐19 pandemic and gave no concerns regarding reduced tolerability under real‐life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long‐lasting negative impact on the clinical care of allergic patients.
This is the first report of an international retrospective survey in atopic diseases investigating practical aspects and tolerability of AIT during the COVID‐19 pandemic. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT, 35% SLIT, and 40% venom AIT in the induction phase of AIT though planned. For the maintenance phase of AIT, SCIT was performed by 75%, SLIT by 89%, and venom AIT by 74% of the respondents as regularly planned. Data indicate a (temporary) undertreatment of AIT, but gave no concerns regarding reduced tolerability under real‐life circumstances. Abbreviations: AIT, allergen immunotherapy; COVID‐19, Coronavirus disease 2019; SCIT, subcutaneous Immunotherapy; SLIT, sublingual Immunotherapy; VIT, venom immunotherapy.</description><identifier>ISSN: 0105-4538</identifier><identifier>EISSN: 1398-9995</identifier><identifier>DOI: 10.1111/all.14793</identifier><identifier>PMID: 33655519</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>allergen immunotherapy (AIT) ; Allergens ; Allergies ; Atopy ; Coronaviruses ; COVID-19 ; Immunotherapy ; Original ; ORIGINAL ARTICLES ; pandemic ; Pandemics ; Patients ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; survey ; Venom</subject><ispartof>Allergy (Copenhagen), 2021-11, Vol.76 (11), p.3504-3516</ispartof><rights>2021 The Authors. published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4713-83b28a51e46158c11ed102afe8b0bee448d40549952606ecbe93cacefb496c163</citedby><cites>FETCH-LOGICAL-c4713-83b28a51e46158c11ed102afe8b0bee448d40549952606ecbe93cacefb496c163</cites><orcidid>0000-0001-8710-0829 ; 0000-0002-8055-0103 ; 0000-0003-0088-913X ; 0000-0002-2455-0192 ; 0000-0003-4019-5765 ; 0000-0003-3629-4293 ; 0000-0002-4517-1749 ; 0000-0002-1963-499X ; 0000-0002-8830-058X ; 0000-0001-9568-6882 ; 0000-0002-3042-0765 ; 0000-0002-3524-9952 ; 0000-0003-4516-0369 ; 0000-0001-5228-471X ; 0000-0001-7994-364X ; 0000-0002-8747-4799 ; 0000-0003-4705-3583 ; 0000-0002-5528-8043 ; 0000-0002-8745-0228 ; 0000-0002-0492-5663 ; 0000-0001-7203-0813 ; 0000-0003-4374-9639</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fall.14793$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fall.14793$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33655519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pfaar, Oliver</creatorcontrib><creatorcontrib>Agache, Ioana</creatorcontrib><creatorcontrib>Bonini, Matteo</creatorcontrib><creatorcontrib>Brough, Helen Annaruth</creatorcontrib><creatorcontrib>Chivato, Tomás</creatorcontrib><creatorcontrib>Del Giacco, Stefano R.</creatorcontrib><creatorcontrib>Gawlik, Radoslaw</creatorcontrib><creatorcontrib>Gelincik, Aslı</creatorcontrib><creatorcontrib>Hoffmann‐Sommergruber, Karin</creatorcontrib><creatorcontrib>Jutel, Marek</creatorcontrib><creatorcontrib>Klimek, Ludger</creatorcontrib><creatorcontrib>Knol, Edward F.</creatorcontrib><creatorcontrib>Lauerma, Antti</creatorcontrib><creatorcontrib>Ollert, Markus</creatorcontrib><creatorcontrib>O’Mahony, Liam</creatorcontrib><creatorcontrib>Mortz, Charlotte G.</creatorcontrib><creatorcontrib>Palomares, Oscar</creatorcontrib><creatorcontrib>Riggioni, Carmen</creatorcontrib><creatorcontrib>Schwarze, Jürgen</creatorcontrib><creatorcontrib>Skypala, Isabel</creatorcontrib><creatorcontrib>Torres, María José</creatorcontrib><creatorcontrib>Untersmayr, Eva</creatorcontrib><creatorcontrib>Walusiak‐Skorupa, Jolanta</creatorcontrib><creatorcontrib>Chaker, Adam</creatorcontrib><creatorcontrib>Giovannini, Mattia</creatorcontrib><creatorcontrib>Heffler, Enrico</creatorcontrib><creatorcontrib>Jensen‐Jarolim, Erika</creatorcontrib><creatorcontrib>Quecchia, Cristina</creatorcontrib><creatorcontrib>Sandoval‐Ruballos, Mónica</creatorcontrib><creatorcontrib>Sahiner, Umit</creatorcontrib><creatorcontrib>Tomić Spirić, Vesna</creatorcontrib><creatorcontrib>Alvaro‐Lozano, Montserrat</creatorcontrib><title>COVID‐19 pandemic and allergen immunotherapy—an EAACI survey</title><title>Allergy (Copenhagen)</title><addtitle>Allergy</addtitle><description>Background
As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.
Methods
Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set‐up a web‐based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine.
Results
417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID‐19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2).
Conclusions
This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID‐19 pandemic and gave no concerns regarding reduced tolerability under real‐life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long‐lasting negative impact on the clinical care of allergic patients.
This is the first report of an international retrospective survey in atopic diseases investigating practical aspects and tolerability of AIT during the COVID‐19 pandemic. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT, 35% SLIT, and 40% venom AIT in the induction phase of AIT though planned. For the maintenance phase of AIT, SCIT was performed by 75%, SLIT by 89%, and venom AIT by 74% of the respondents as regularly planned. Data indicate a (temporary) undertreatment of AIT, but gave no concerns regarding reduced tolerability under real‐life circumstances. Abbreviations: AIT, allergen immunotherapy; COVID‐19, Coronavirus disease 2019; SCIT, subcutaneous Immunotherapy; SLIT, sublingual Immunotherapy; VIT, venom immunotherapy.</description><subject>allergen immunotherapy (AIT)</subject><subject>Allergens</subject><subject>Allergies</subject><subject>Atopy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Immunotherapy</subject><subject>Original</subject><subject>ORIGINAL ARTICLES</subject><subject>pandemic</subject><subject>Pandemics</subject><subject>Patients</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>survey</subject><subject>Venom</subject><issn>0105-4538</issn><issn>1398-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kMtOAjEUhhujEUQXvoCZxJWLgXZ6od0YCaKSkLBRt02nHGDIXLDDYNjxCC58Qp7EIkh04dmcxfnynT8_QpcEN4mflknTJmFtRY9QnVAlQ6UUP0Z1TDAPGaeyhs7KcoYxbkcKn6IapYJzTlQd3XWHr_37zfqDqGBu8hFkiQ38DrwT3ATyIMmyKi8WU3BmvtqsP00e9Dqdbj8oK7eE1Tk6GZu0hIv9bqCXh95z9ykcDB_73c4gtKxNaChpHEnDCTBBuLSEwIjgyIxBxjgGYEyOGObM544EFmBjUNQaC-OYKWGJoA10u_POqziDkYV84Uyq5y7JjFvpwiT67yVPpnpSLLXEhIo29oLrvcAVbxWUCz0rKpf7zDriUkgspdi-udlR1hVl6WB8-ECw3patfTH6u2zPXv2OdCB_2vVAawe8Jyms_jfpzmCwU34BOkCKBA</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Pfaar, Oliver</creator><creator>Agache, Ioana</creator><creator>Bonini, Matteo</creator><creator>Brough, Helen Annaruth</creator><creator>Chivato, Tomás</creator><creator>Del Giacco, Stefano R.</creator><creator>Gawlik, Radoslaw</creator><creator>Gelincik, Aslı</creator><creator>Hoffmann‐Sommergruber, Karin</creator><creator>Jutel, Marek</creator><creator>Klimek, Ludger</creator><creator>Knol, Edward F.</creator><creator>Lauerma, Antti</creator><creator>Ollert, Markus</creator><creator>O’Mahony, Liam</creator><creator>Mortz, Charlotte G.</creator><creator>Palomares, Oscar</creator><creator>Riggioni, Carmen</creator><creator>Schwarze, Jürgen</creator><creator>Skypala, Isabel</creator><creator>Torres, María José</creator><creator>Untersmayr, Eva</creator><creator>Walusiak‐Skorupa, Jolanta</creator><creator>Chaker, Adam</creator><creator>Giovannini, Mattia</creator><creator>Heffler, Enrico</creator><creator>Jensen‐Jarolim, Erika</creator><creator>Quecchia, Cristina</creator><creator>Sandoval‐Ruballos, Mónica</creator><creator>Sahiner, Umit</creator><creator>Tomić Spirić, Vesna</creator><creator>Alvaro‐Lozano, Montserrat</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8710-0829</orcidid><orcidid>https://orcid.org/0000-0002-8055-0103</orcidid><orcidid>https://orcid.org/0000-0003-0088-913X</orcidid><orcidid>https://orcid.org/0000-0002-2455-0192</orcidid><orcidid>https://orcid.org/0000-0003-4019-5765</orcidid><orcidid>https://orcid.org/0000-0003-3629-4293</orcidid><orcidid>https://orcid.org/0000-0002-4517-1749</orcidid><orcidid>https://orcid.org/0000-0002-1963-499X</orcidid><orcidid>https://orcid.org/0000-0002-8830-058X</orcidid><orcidid>https://orcid.org/0000-0001-9568-6882</orcidid><orcidid>https://orcid.org/0000-0002-3042-0765</orcidid><orcidid>https://orcid.org/0000-0002-3524-9952</orcidid><orcidid>https://orcid.org/0000-0003-4516-0369</orcidid><orcidid>https://orcid.org/0000-0001-5228-471X</orcidid><orcidid>https://orcid.org/0000-0001-7994-364X</orcidid><orcidid>https://orcid.org/0000-0002-8747-4799</orcidid><orcidid>https://orcid.org/0000-0003-4705-3583</orcidid><orcidid>https://orcid.org/0000-0002-5528-8043</orcidid><orcidid>https://orcid.org/0000-0002-8745-0228</orcidid><orcidid>https://orcid.org/0000-0002-0492-5663</orcidid><orcidid>https://orcid.org/0000-0001-7203-0813</orcidid><orcidid>https://orcid.org/0000-0003-4374-9639</orcidid></search><sort><creationdate>202111</creationdate><title>COVID‐19 pandemic and allergen immunotherapy—an EAACI survey</title><author>Pfaar, Oliver ; Agache, Ioana ; Bonini, Matteo ; Brough, Helen Annaruth ; Chivato, Tomás ; Del Giacco, Stefano R. ; Gawlik, Radoslaw ; Gelincik, Aslı ; Hoffmann‐Sommergruber, Karin ; Jutel, Marek ; Klimek, Ludger ; Knol, Edward F. ; Lauerma, Antti ; Ollert, Markus ; O’Mahony, Liam ; Mortz, Charlotte G. ; Palomares, Oscar ; Riggioni, Carmen ; Schwarze, Jürgen ; Skypala, Isabel ; Torres, María José ; Untersmayr, Eva ; Walusiak‐Skorupa, Jolanta ; Chaker, Adam ; Giovannini, Mattia ; Heffler, Enrico ; Jensen‐Jarolim, Erika ; Quecchia, Cristina ; Sandoval‐Ruballos, Mónica ; Sahiner, Umit ; Tomić Spirić, Vesna ; Alvaro‐Lozano, Montserrat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4713-83b28a51e46158c11ed102afe8b0bee448d40549952606ecbe93cacefb496c163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>allergen immunotherapy (AIT)</topic><topic>Allergens</topic><topic>Allergies</topic><topic>Atopy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Immunotherapy</topic><topic>Original</topic><topic>ORIGINAL ARTICLES</topic><topic>pandemic</topic><topic>Pandemics</topic><topic>Patients</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>survey</topic><topic>Venom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pfaar, Oliver</creatorcontrib><creatorcontrib>Agache, Ioana</creatorcontrib><creatorcontrib>Bonini, Matteo</creatorcontrib><creatorcontrib>Brough, Helen Annaruth</creatorcontrib><creatorcontrib>Chivato, Tomás</creatorcontrib><creatorcontrib>Del Giacco, Stefano R.</creatorcontrib><creatorcontrib>Gawlik, Radoslaw</creatorcontrib><creatorcontrib>Gelincik, Aslı</creatorcontrib><creatorcontrib>Hoffmann‐Sommergruber, Karin</creatorcontrib><creatorcontrib>Jutel, Marek</creatorcontrib><creatorcontrib>Klimek, Ludger</creatorcontrib><creatorcontrib>Knol, Edward F.</creatorcontrib><creatorcontrib>Lauerma, Antti</creatorcontrib><creatorcontrib>Ollert, Markus</creatorcontrib><creatorcontrib>O’Mahony, Liam</creatorcontrib><creatorcontrib>Mortz, Charlotte G.</creatorcontrib><creatorcontrib>Palomares, Oscar</creatorcontrib><creatorcontrib>Riggioni, Carmen</creatorcontrib><creatorcontrib>Schwarze, Jürgen</creatorcontrib><creatorcontrib>Skypala, Isabel</creatorcontrib><creatorcontrib>Torres, María José</creatorcontrib><creatorcontrib>Untersmayr, Eva</creatorcontrib><creatorcontrib>Walusiak‐Skorupa, Jolanta</creatorcontrib><creatorcontrib>Chaker, Adam</creatorcontrib><creatorcontrib>Giovannini, Mattia</creatorcontrib><creatorcontrib>Heffler, Enrico</creatorcontrib><creatorcontrib>Jensen‐Jarolim, Erika</creatorcontrib><creatorcontrib>Quecchia, Cristina</creatorcontrib><creatorcontrib>Sandoval‐Ruballos, Mónica</creatorcontrib><creatorcontrib>Sahiner, Umit</creatorcontrib><creatorcontrib>Tomić Spirić, Vesna</creatorcontrib><creatorcontrib>Alvaro‐Lozano, Montserrat</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Allergy (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pfaar, Oliver</au><au>Agache, Ioana</au><au>Bonini, Matteo</au><au>Brough, Helen Annaruth</au><au>Chivato, Tomás</au><au>Del Giacco, Stefano R.</au><au>Gawlik, Radoslaw</au><au>Gelincik, Aslı</au><au>Hoffmann‐Sommergruber, Karin</au><au>Jutel, Marek</au><au>Klimek, Ludger</au><au>Knol, Edward F.</au><au>Lauerma, Antti</au><au>Ollert, Markus</au><au>O’Mahony, Liam</au><au>Mortz, Charlotte G.</au><au>Palomares, Oscar</au><au>Riggioni, Carmen</au><au>Schwarze, Jürgen</au><au>Skypala, Isabel</au><au>Torres, María José</au><au>Untersmayr, Eva</au><au>Walusiak‐Skorupa, Jolanta</au><au>Chaker, Adam</au><au>Giovannini, Mattia</au><au>Heffler, Enrico</au><au>Jensen‐Jarolim, Erika</au><au>Quecchia, Cristina</au><au>Sandoval‐Ruballos, Mónica</au><au>Sahiner, Umit</au><au>Tomić Spirić, Vesna</au><au>Alvaro‐Lozano, Montserrat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19 pandemic and allergen immunotherapy—an EAACI survey</atitle><jtitle>Allergy (Copenhagen)</jtitle><addtitle>Allergy</addtitle><date>2021-11</date><risdate>2021</risdate><volume>76</volume><issue>11</issue><spage>3504</spage><epage>3516</epage><pages>3504-3516</pages><issn>0105-4538</issn><eissn>1398-9995</eissn><abstract>Background
As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.
Methods
Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set‐up a web‐based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine.
Results
417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID‐19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2).
Conclusions
This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID‐19 pandemic and gave no concerns regarding reduced tolerability under real‐life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long‐lasting negative impact on the clinical care of allergic patients.
This is the first report of an international retrospective survey in atopic diseases investigating practical aspects and tolerability of AIT during the COVID‐19 pandemic. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT, 35% SLIT, and 40% venom AIT in the induction phase of AIT though planned. For the maintenance phase of AIT, SCIT was performed by 75%, SLIT by 89%, and venom AIT by 74% of the respondents as regularly planned. Data indicate a (temporary) undertreatment of AIT, but gave no concerns regarding reduced tolerability under real‐life circumstances. Abbreviations: AIT, allergen immunotherapy; COVID‐19, Coronavirus disease 2019; SCIT, subcutaneous Immunotherapy; SLIT, sublingual Immunotherapy; VIT, venom immunotherapy.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>33655519</pmid><doi>10.1111/all.14793</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-8710-0829</orcidid><orcidid>https://orcid.org/0000-0002-8055-0103</orcidid><orcidid>https://orcid.org/0000-0003-0088-913X</orcidid><orcidid>https://orcid.org/0000-0002-2455-0192</orcidid><orcidid>https://orcid.org/0000-0003-4019-5765</orcidid><orcidid>https://orcid.org/0000-0003-3629-4293</orcidid><orcidid>https://orcid.org/0000-0002-4517-1749</orcidid><orcidid>https://orcid.org/0000-0002-1963-499X</orcidid><orcidid>https://orcid.org/0000-0002-8830-058X</orcidid><orcidid>https://orcid.org/0000-0001-9568-6882</orcidid><orcidid>https://orcid.org/0000-0002-3042-0765</orcidid><orcidid>https://orcid.org/0000-0002-3524-9952</orcidid><orcidid>https://orcid.org/0000-0003-4516-0369</orcidid><orcidid>https://orcid.org/0000-0001-5228-471X</orcidid><orcidid>https://orcid.org/0000-0001-7994-364X</orcidid><orcidid>https://orcid.org/0000-0002-8747-4799</orcidid><orcidid>https://orcid.org/0000-0003-4705-3583</orcidid><orcidid>https://orcid.org/0000-0002-5528-8043</orcidid><orcidid>https://orcid.org/0000-0002-8745-0228</orcidid><orcidid>https://orcid.org/0000-0002-0492-5663</orcidid><orcidid>https://orcid.org/0000-0001-7203-0813</orcidid><orcidid>https://orcid.org/0000-0003-4374-9639</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0105-4538 |
| ispartof | Allergy (Copenhagen), 2021-11, Vol.76 (11), p.3504-3516 |
| issn | 0105-4538 1398-9995 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8013670 |
| source | Wiley Online Library Free Content; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
| subjects | allergen immunotherapy (AIT) Allergens Allergies Atopy Coronaviruses COVID-19 Immunotherapy Original ORIGINAL ARTICLES pandemic Pandemics Patients SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 survey Venom |
| title | COVID‐19 pandemic and allergen immunotherapy—an EAACI survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T01%3A31%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019%20pandemic%20and%20allergen%20immunotherapy%E2%80%94an%20EAACI%20survey&rft.jtitle=Allergy%20(Copenhagen)&rft.au=Pfaar,%20Oliver&rft.date=2021-11&rft.volume=76&rft.issue=11&rft.spage=3504&rft.epage=3516&rft.pages=3504-3516&rft.issn=0105-4538&rft.eissn=1398-9995&rft_id=info:doi/10.1111/all.14793&rft_dat=%3Cproquest_pubme%3E2586808866%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586808866&rft_id=info:pmid/33655519&rfr_iscdi=true |